August 6, 2021
Kissei Pharmaceutical said on August 5 that it struck a sublicense agreement with Chinese drug maker Inmagene Biopharmaceuticals for the rights to develop and commercialize the spleen tyrosine kinase inhibitor fostamatinib in China. Under the deal, Inmagene will be responsible...read more